Page 16 - norgine-annual-report-2016

Executive Looking forward

Team to 2017

Norgine’s performance in 2016 continued to create
a solid platform to achieve its Vision 2020. Norgine
Peter Stein Peter Martin continued to deliver strong sales of its core products
Chief Executive Officer Chief Operating Officer
despite challenging market conditions and progressed
several drivers of future growth.

In 2017, Norgine’s management will continue to work
Christopher Bath Paul Pay towards its strategic objectives and realising its long-term
Chief Financial Officer Chief Business Development Officer vision, to be widely recognised as the ‘go to’ European
specialist pharma company partner of choice.

Norgine will continue to focus on using its expertise
Kenneth Scrimgeour Sheila Hopkins and established infrastructure to ‘win’ global and local
Chief Commercial Officer Chief Legal Officer partnership opportunities to expand its product portfolio
in gastroenterology, hepatology, cancer and supportive
care, as well as other specialist areas that can be
effectively accessed through its infrastructure.
Dr Alastair Benbow Philippe Caroff New asset acquisitions will remain a priority for
Chief Development and VP, Manufacturing & Supply
Medical Officer Norgine and a number of registrations, launches and
reimbursements are anticipated for 2017, including:

Tara Barry PLENVU is expected to be submitted in the US and approved in Europe
®
Chief Human Resources Officer
LYMPHOSEEK is expected to be launched in Norgine’s markets
®
ZIVEREL is expected to be launched in Norgine’s markets
®
MOVIPREP is expected to be launched in further countries through the Takeda CIS partnership
®
MOVICOL Ready to Take is expected to be launched in all remaining Norgine’s markets
®
MUGARD is expected to be launched in all remaining Norgine’s markets
®

References
All product names mentioned in this report are trademarks owned by or
licensed to the Norgine group of companies, unless otherwise noted.
© Norgine. All rights reserved.

15 16